EUR/USD likely to find a peak near 1.25: UBS
Investing.com -- Tandem Diabetes Care, Inc. (NASDAQ:TNDM) saw its stock jump 6.2% after reporting first quarter earnings that exceeded analyst expectations and reaffirming strong full-year guidance.
The insulin delivery and diabetes technology company posted revenue of $234.4 million for the quarter, surpassing the consensus estimate of $220.3 million and marking a 22% YoY increase. However, Tandem reported a wider-than-expected loss, with adjusted EPS of -$1.97 compared to analyst projections of -$0.60.
Tandem’s robust sales growth was driven by a 19% increase in U.S. pump sales and record international sales of $83.8 million. The company shipped over 17,000 pumps in the U.S. and more than 11,000 pumps internationally during the quarter.
"The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States," said John Sheridan, president and CEO of Tandem Diabetes Care.
Despite the earnings miss, Tandem reaffirmed its full-year 2025 guidance, projecting revenue between $997 million and $1.007 billion, in line with the consensus estimate of $998.7 million. The company expects U.S. sales of $725-730 million and international sales of $272-277 million.
Tandem also anticipates a gross margin of approximately 54% and an adjusted EBITDA margin of about 3% for the full year.
The company’s performance reflects growing adoption of its diabetes management technologies, with approximately 30% of U.S. lives now covered through pharmacy benefits for its Tandem Mobi device.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.